Venetoclax Is Safe And Efficacious In Relapsed/Refractory Aml

Chezi Ganzel,Ron Ram,Alexander Gural,Ofir Wolach,Sharon Gino-Moor,Vladimir Vainstein,Boaz Nachmias,Arie Apel,Maya Koren-Michowitz,Oren Pasvolsky,Ronit Yerushalmi,Ivetta Danylesko, Yoseph Cohen,Galit Perets,Yakir Moshe,Miri Zektzer,Shay Yeganeh,Jacob M. Rowe,Yishai Ofran

BLOOD（2019）

引用 28|浏览30

暂无评分

摘要

Introduction: On November 2018 the FDA approved the treatment of venetoclax together with hypomethylating agent (HMA) or low dose cytarabine (LDAC) for newly diagnosed AML patients who cannot tolerate intensive chemotherapy. There is limited data regarding the efficacy and safety of venetoclax in the setting of relapsed/refractory patients who received intensive chemotherapy for their disease.

查看译文

关键词

aml

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要